Overview
Endobronchial bleeding is a common complication of bronchoscopy. Major bleeding, although rare, can be life threatening and often requires advanced therapeutic interventional pulmonary procedures which are not widely available. Minor bleeding can negatively impact outcomes such as diagnostic yield, sample size and bronchoscopy duration. Both adrenaline and tranexamic acid are successfully used topically for hemostasis during diagnostic bronchoscopy. The aim of this study is to evaluate the efficacy of prophylactically applied adrenaline and tranexamic acid in bleeding prevention during diagnostic bronchoscopy.
Eligibility
Inclusion Criteria:
- All patients undergoing diagnostic bronchoscopy with sampling (including transbronchial biopsy, endobronchial forceps biopsy, brushing, transbronchial needle aspiration)
- Signed informed consent
Exclusion Criteria:
- Any existing contraindication for diagnostic bronchoscopy
- Coagulopathy (PV INR > 1.3)
- Thrombocytopenia (<50x10*9 or anemia (Hgb <80 g/L)
- DOAC, LMWH or antiplatelet drug therapy
- Thrombophilia, history of pulmonary embolism or deep vein thrombosis
- Contraindication for endobronchial application of adrenaline
- Uncontrolled coronary artery disease, cerebrovascular disease or arrhythmia
- Uncontrolled pulmonary hypertension
- Cardiovascular decompensation
- Severe hypoxia (PaO2 <60mmHg, SaO2 <90% with an FiO2 >=60%)